2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
|Articles|November 1, 1999
The American Journal of Managed Care
- November 1999
- Volume 5
- Issue 11
Paying for HIV/AIDS Care at the Turn of the Century
Author(s)Joseph F. O'Neil, MD, MPH
Advertisement
Articles in this issue
almost 27 years ago
Doctor, I'm Having a Heart Attack, What Should I Do?almost 27 years ago
Estimates of Costs of Primary Care Physician Turnoveralmost 27 years ago
Developing a Managed Care Delivery System for People with HIV/AIDSAdvertisement
Related to this article
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5